The Biologics Contract Development and Manufacturing Organization (CDMO) Market study analyzes and forecasts the market size across 6 regions and 24 countries for diverse segments including By Type (Mammalian, Microbial), By Product (Biologics, Biosimilars).
The Biologics Contract Development and Manufacturing Organization (CDMO) Market is witnessing robust growth, driven by the increasing demand for outsourcing services in the biopharmaceutical industry. Biologics CDMOs provide specialized expertise in the development, manufacturing, and testing of biopharmaceutical products, including monoclonal antibodies, recombinant proteins, and gene therapies. This market caters to pharmaceutical and biotechnology companies seeking cost-effective and scalable solutions for bringing biologics to market. CDMOs are investing in state-of-the-art facilities, technology platforms, and regulatory compliance to meet the complex requirements of biologics development. With the continuous growth of the biopharmaceutical industry and the emphasis on outsourcing to streamline operations, the Biologics CDMO Market is poised for sustained expansion, playing a crucial role in the global biologics supply chain.
The most prominent trend in the Biologics Contract Development and Manufacturing Organization (CDMO) Market is the increasing outsourcing of biologics development and manufacturing by pharmaceutical and biotechnology companies. As the biopharmaceutical industry experiences a surge in demand for innovative biologic therapies, there is a notable trend towards companies outsourcing their development and manufacturing processes to specialized CDMOs. This trend is driven by the complexities of biologics production, the need for specialized expertise, and the desire for cost-efficient and scalable solutions. The Biologics CDMO market is witnessing a growing number of collaborations and partnerships as companies seek external expertise to navigate the intricate landscape of biologics development and manufacturing.
A major driver propelling the Biologics Contract Development and Manufacturing Organization (CDMO) Market is the rise in biologics approvals and the consequent expansion of the biopharmaceutical market. With an increasing number of biologic drugs receiving regulatory approvals, there is heightened demand for manufacturing capabilities to meet the market demand for these complex therapies. The need for efficient and compliant production processes drives pharmaceutical and biotech companies to engage with specialized CDMOs that can offer expertise in biologics development, manufacturing, and regulatory compliance. The expanding landscape of biologics in various therapeutic areas acts as a strong driver for the growth of the Biologics CDMO market.
An emerging opportunity in the Biologics Contract Development and Manufacturing Organization (CDMO) Market lies in providing customized solutions and flexible manufacturing platforms. Market players have the potential to differentiate themselves by offering tailored services that meet the specific needs of their clients. This opportunity involves developing flexible manufacturing processes that can accommodate different scales of production, diverse types of biologics, and varying client requirements. CDMOs that can adapt to the evolving landscape of biopharmaceuticals and provide customized solutions stand to capture a significant market share. Seizing this opportunity allows companies to position themselves as strategic partners for pharmaceutical and biotech firms seeking adaptable and client-centric biologics development and manufacturing services.
By Type
By Product
Biologics
-Monoclonal
-Recombinant Proteins
-Antisense and Molecular Therapy
-Vaccines
-Others
Biosimilars
By Region
• Deepen your industry insights and navigate uncertainties for strategy formulation, CAPEX, and Operational decisions
• Gain access to detailed insights on the Biologics Contract Development and Manufacturing Organization (CDMO) Market, encompassing current market size, growth trends, and forecasts till 2030.
• Access detailed competitor analysis, enabling competitive advantage through a thorough understanding of market players, strategies, and potential differentiation opportunities
• Stay ahead of the curve with insights on technological advancements, innovations, and upcoming trends
• Identify lucrative investment avenues and expansion opportunities within the Biologics Contract Development and Manufacturing Organization (CDMO) Market industry, guided by robust, data-backed analysis.
• Understand regional and global markets through country-wise analysis, regional market potential, regulatory nuances, and dynamics
• Execute strategies with confidence and speed through information, analytics, and insights on the industry value chain
• Corporate leaders, strategists, financial experts, shareholders, asset managers, and governmental representatives can make long-term planning scenarios and build an integrated and timely understanding of market dynamics
• Benefit from tailored solutions and expert consultation based on report insights, providing personalized strategies aligned with specific business needs.
TABLE OF CONTENTS
1 INTRODUCTION TO 2024 Biologics Contract Development and Manufacturing Organization (CDMO) Markets
1.1 Market Overview
1.2 Quick Facts
1.3 Scope/Objective of the Study
1.4 Market Definition
1.5 Countries and Regions Analyzed
1.6 Units, Currency, and Conversions
1.7 Industry Value Chain
2 RESEARCH METHODOLOGY
2.1 Market Size Estimation
2.2 Sources and Research Methodology
2.3 Data Triangulation
2.4 Assumptions and Limitations
3 EXECUTIVE SUMMARY
3.1 Global Biologics Contract Development and Manufacturing Organization (CDMO) Market Size Outlook, $ Million, 2021 to 2030
3.2 Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook by Type, $ Million, 2021 to 2030
3.3 Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook by Product, $ Million, 2021 to 2030
3.4 Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook by Application, $ Million, 2021 to 2030
3.5 Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook by Key Countries, $ Million, 2021 to 2030
4 MARKET DYNAMICS
4.1 Key Driving Forces of Biologics Contract Development and Manufacturing Organization (CDMO) Market Industry
4.2 Key Market Trends in Biologics Contract Development and Manufacturing Organization (CDMO) Market Industry
4.3 Potential Opportunities in Biologics Contract Development and Manufacturing Organization (CDMO) Market Industry
4.4 Key Challenges in Biologics Contract Development and Manufacturing Organization (CDMO) Market Industry
5 MARKET FACTOR ANALYSIS
5.1 Competitive Landscape
5.1.1 Global Biologics Contract Development and Manufacturing Organization (CDMO) Market Share by Company
5.1.2 Product Offerings by Company
5.2 Porter’s Five Forces Analysis
6 GROWTH OUTLOOK ACROSS SCENARIOS
6.1 Growth Analysis-Case Scenario Definitions
6.2 Low Growth Scenario Forecasts
6.3 Reference Growth Scenario Forecasts
6.4 High Growth Scenario Forecasts
7 GLOBAL Biologics Contract Development and Manufacturing Organization (CDMO) Market OUTLOOK BY SEGMENTS
7.1 Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook by Segments
By Type
Mammalian
Microbial
By Product
Biologics
-Monoclonal
-Recombinant Proteins
-Antisense and Molecular Therapy
-Vaccines
-Others
Biosimilars
8 NORTH AMERICA Biologics Contract Development and Manufacturing Organization (CDMO) Market ANALYSIS AND OUTLOOK TO 2030
8.1 Introduction to North America Biologics Contract Development and Manufacturing Organization (CDMO) Markets in 2024
8.2 North America Biologics Contract Development and Manufacturing Organization (CDMO) Market Size Outlook by Country, 2021-2030
8.2.1 United States
8.2.2 Canada
8.2.3 Mexico
8.3 North America Biologics Contract Development and Manufacturing Organization (CDMO) Market size Outlook by Segments, 2021-2030
By Type
Mammalian
Microbial
By Product
Biologics
-Monoclonal
-Recombinant Proteins
-Antisense and Molecular Therapy
-Vaccines
-Others
Biosimilars
9 EUROPE Biologics Contract Development and Manufacturing Organization (CDMO) Market ANALYSIS AND OUTLOOK TO 2030
9.1 Introduction to Europe Biologics Contract Development and Manufacturing Organization (CDMO) Markets in 2024
9.2 Europe Biologics Contract Development and Manufacturing Organization (CDMO) Market Size Outlook by Country, 2021-2030
9.2.1 Germany
9.2.2 France
9.2.3 Spain
9.2.4 United Kingdom
9.2.4 Italy
9.2.5 Russia
9.2.6 Norway
9.2.7 Rest of Europe
9.3 Europe Biologics Contract Development and Manufacturing Organization (CDMO) Market size Outlook by Segments, 2021-2030
By Type
Mammalian
Microbial
By Product
Biologics
-Monoclonal
-Recombinant Proteins
-Antisense and Molecular Therapy
-Vaccines
-Others
Biosimilars
10 ASIA PACIFIC Biologics Contract Development and Manufacturing Organization (CDMO) Market ANALYSIS AND OUTLOOK TO 2030
10.1 Introduction to Asia Pacific Biologics Contract Development and Manufacturing Organization (CDMO) Markets in 2024
10.2 Asia Pacific Biologics Contract Development and Manufacturing Organization (CDMO) Market Size Outlook by Country, 2021-2030
10.2.1 China
10.2.2 India
10.2.3 Japan
10.2.4 South Korea
10.2.5 Indonesia
10.2.6 Malaysia
10.2.7 Australia
10.2.8 Rest of Asia Pacific
10.3 Asia Pacific Biologics Contract Development and Manufacturing Organization (CDMO) Market size Outlook by Segments, 2021-2030
By Type
Mammalian
Microbial
By Product
Biologics
-Monoclonal
-Recombinant Proteins
-Antisense and Molecular Therapy
-Vaccines
-Others
Biosimilars
11 SOUTH AMERICA Biologics Contract Development and Manufacturing Organization (CDMO) Market ANALYSIS AND OUTLOOK TO 2030
11.1 Introduction to South America Biologics Contract Development and Manufacturing Organization (CDMO) Markets in 2024
11.2 South America Biologics Contract Development and Manufacturing Organization (CDMO) Market Size Outlook by Country, 2021-2030
11.2.1 Brazil
11.2.2 Argentina
11.2.3 Rest of South America
11.3 South America Biologics Contract Development and Manufacturing Organization (CDMO) Market size Outlook by Segments, 2021-2030
By Type
Mammalian
Microbial
By Product
Biologics
-Monoclonal
-Recombinant Proteins
-Antisense and Molecular Therapy
-Vaccines
-Others
Biosimilars
12 MIDDLE EAST AND AFRICA Biologics Contract Development and Manufacturing Organization (CDMO) Market ANALYSIS AND OUTLOOK TO 2030
12.1 Introduction to Middle East and Africa Biologics Contract Development and Manufacturing Organization (CDMO) Markets in 2024
12.2 Middle East and Africa Biologics Contract Development and Manufacturing Organization (CDMO) Market Size Outlook by Country, 2021-2030
12.2.1 Saudi Arabia
12.2.2 UAE
12.2.3 Oman
12.2.4 Rest of Middle East
12.2.5 Egypt
12.2.6 Nigeria
12.2.7 South Africa
12.2.8 Rest of Africa
12.3 Middle East and Africa Biologics Contract Development and Manufacturing Organization (CDMO) Market size Outlook by Segments, 2021-2030
By Type
Mammalian
Microbial
By Product
Biologics
-Monoclonal
-Recombinant Proteins
-Antisense and Molecular Therapy
-Vaccines
-Others
Biosimilars
13 COMPANY PROFILES
13.1 Company Snapshot
13.2 SWOT Profiles
13.3 Products and Services
13.4 Recent Developments
13.5 Financial Profile
List of Companies
Boehringer Ingelheim Group
Wuxi Biologics
Samsung Biologics
Lonza Group
Fujifilm Diosynth Biotechnologies USA Inc.
Toyobo Co. Limited
Parexel International Corporation
Icon PLC
Binex Co. Limited
JRS Pharma
Rentschler Biotechnologies
AGC Biologics
Sandoz Biopharmaceuticals (Novartis AG)
Catalent Inc.
AbbVie Contract Manufacturing
14 APPENDIX
14.1 Customization Offerings
14.2 Subscription Services
14.3 Related Reports
14.4 Publisher Expertise
By Type
By Product
Biologics
-Monoclonal
-Recombinant Proteins
-Antisense and Molecular Therapy
-Vaccines
-Others
Biosimilars
By Region
The global Biologics Contract Development and Manufacturing Organization (CDMO) Market is one of the lucrative growth markets, poised to register a 12.4 growth (CAGR) between 2024 and 2032.
Emerging Markets across Asia Pacific, Europe, and Americas present robust growth prospects.
Boehringer Ingelheim Group, Wuxi Biologics, Samsung Biologics, Lonza Group, Fujifilm Diosynth Biotechnologies USA Inc., Toyobo Co. Limited, Parexel International Corporation, Icon PLC, Binex Co. Limited, JRS Pharma, Rentschler Biotechnologies, AGC Biologics, Sandoz Biopharmaceuticals (Novartis AG), Catalent Inc., AbbVie Contract Manufacturing
Base Year- 2023; Estimated Year- 2024; Historic Period- 2018-2023; Forecast period- 2024 to 2030; Currency: USD; Volume